Literature DB >> 27366439

Olanzapine-Induced Malignant Neuroleptic Syndrome.

Tuba Berra Sarıtaş1, Barış Çankaya2, Alper Yosunkaya1.   

Abstract

Neuroleptic malignant syndrome (NMS), caused by antipsychotic therapy, shows itself with mental status alteration, high fever, autonomic dysfunction, and muscle rigidity. It is a rare idiosyncratic reaction with mortality risk. The etiology is still unknown. NMS-related mortality and morbidity can be decreased by cessation of the used drug and aggressive treatment. Olanzapine is a thienobenzodiazepine, a member of atypical antipsychotic drugs; its structure and effects on neurotransmitters resemble clozapine. Here we report a case of bipolar disorder receiving olanzapine therapy for 10 years, who developed NMS without rigidity. We emphasized the importance of early hydration and hemodiafiltration therapy.

Entities:  

Keywords:  Neuroleptic malignant syndrome; hemodiafiltration; olanzapine; rigidity

Year:  2014        PMID: 27366439      PMCID: PMC4894178          DOI: 10.5152/TJAR.2014.46704

Source DB:  PubMed          Journal:  Turk J Anaesthesiol Reanim        ISSN: 2149-276X


  11 in total

1.  Olanzapine induced "typical" neuroleptic malignant syndrome.

Authors:  Joseph S Goveas; Adriana Hermida
Journal:  J Clin Psychopharmacol       Date:  2003-02       Impact factor: 3.153

2.  A prospective analysis of 24 episodes of neuroleptic malignant syndrome.

Authors:  P Rosebush; T Stewart
Journal:  Am J Psychiatry       Date:  1989-06       Impact factor: 18.112

3.  Risk factors for neuroleptic malignant syndrome. A case-control study.

Authors:  P E Keck; H G Pope; B M Cohen; S L McElroy; A A Nierenberg
Journal:  Arch Gen Psychiatry       Date:  1989-10

Review 4.  Neuroleptic malignant syndrome.

Authors:  J L Levenson
Journal:  Am J Psychiatry       Date:  1985-10       Impact factor: 18.112

5.  Atypical neuroleptic malignant syndrome caused by olanzapine.

Authors:  J Nielsen; A M Bruhn
Journal:  Acta Psychiatr Scand       Date:  2005-09       Impact factor: 6.392

6.  Neuroleptic malignant syndrome: long-term follow-up of 20 cases.

Authors:  H G Pope; H G Aizley; P E Keck; S L McElroy
Journal:  J Clin Psychiatry       Date:  1991-05       Impact factor: 4.384

Review 7.  The neuroleptic malignant and serotonin syndromes.

Authors:  J R Carbone
Journal:  Emerg Med Clin North Am       Date:  2000-05       Impact factor: 2.264

Review 8.  Neuropsychiatric sequelae of neuroleptic malignant syndrome.

Authors:  Martha Sajatovic; Kaizad R Munshi
Journal:  Clin Neuropharmacol       Date:  2005 Jul-Aug       Impact factor: 1.592

9.  Olanzapine-induced neuroleptic malignant syndrome in a patient with paranoid schizophrenia.

Authors:  Ashish Srivastava; Hirabai A Borkar; Sumitkumar Chandak
Journal:  Psychiatry Clin Neurosci       Date:  2008-12-01       Impact factor: 5.188

10.  Neuroleptic malignant syndrome developing after acute overdose with olanzapine and chlorpromazine.

Authors:  Enasio Morris; Digby Green; Andis Graudins
Journal:  J Med Toxicol       Date:  2009-03
View more
  2 in total

1.  [Prolonged neuroleptic malignant syndrome after Haloperidol injection].

Authors:  N Wystub; S Heymel; M Fritzenwanger; P C Schulze; R Pfeifer
Journal:  Med Klin Intensivmed Notfmed       Date:  2017-07-27       Impact factor: 0.840

2.  Neuroleptic Malignant Syndrome in a Patient With Anti-N-Methyl-D-Aspartate Receptor Encephalitis: Case Report and Review of Related Literature.

Authors:  Robert Joseph C Sarmiento; Jose Danilo B Diestro; Athena Kate D Antonio; Mario B Prado; Karen Joy B Adiao; Carissa Paz Dioquino-Maligaso
Journal:  Neurohospitalist       Date:  2021-03-19
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.